Arrowhead Pharmaceuticals, Inc. ARWR

PASADENA, Calif., September 29, 2026--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced its plan to host an R&D webinar on Wednesday, October 14, 2026, at 11:30 AM PDT that will focus on investigational therapy ARO-MAPT and Arrowhead’s central nervous system (CNS) pipeline. The webinar will feature a presentation from Adam Boxer, M.D., Ph.D., Endowed Professor in Memory and Aging in the Department of Neurology at the University of California, San Francisco (UCSF), where he directs t

ADARx is the only maker of RNA-based drugs to go public since 2024 and the first RNAi biotech to price an IPO in the U.S. in more than a decade.

Goldman sees biotech’s recent gains holding up despite macro pressures, supported by deal activity, clinical progress, and a more favorable regulatory backdrop.

Arrowhead Pharmaceuticals (ARWR) has drawn fresh attention after reporting interim Phase 1/2a data for ARO-DIMER-PA, its dual RNA interference candidate targeting atherosclerotic cardiovascular disease due to mixed hyperlipidemia. Arrowhead Pharmaceuticals has been volatile around the interim ARO-DIMER-PA update, with the share price down 19.76% over the past week and 25.65% over the past month. However, the 1 year total shareholder return of 116.62% and 3 year total shareholder return of...

RNAi Therapeutics Expand on Precision Medicine Demand, Advanced Subcutaneous Delivery and Growing Rare Disease ApplicationsDublin, Sept. 18, 2026 (GLOBE NEWSWIRE) -- "RNA Interference Therapeutics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026-2035" has been added to ResearchAndMarkets.com's offering. Global RNA Interference Therapeutics Market to Reach USD 31.4 Billion by 2035 The global RNA interference therapeutics market was valued at USD 4.2 billion in 2025 a

Redemplo is already approved by the U.S. Food and Drug Administration (FDA) to lower very high triglycerides in the rare condition familial chylomicronemia syndrome.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) on Tuesday shared interim topline clinical data from a Phase 1/2a trial. The trial is evaluating ARO-DIMER-PA, the company’s first investigational RNA interference (RNAi) therapeutic dimer for atherosclerotic cardiovascular disease (ASCVD) due to mixed hyperlipidemia. Hyperlipidemia is defined by an excess of fats, or lipids—such as cholesterol and triglycerides—in the blood. Read Also: Arrowhead Drug Shows Strong Efficacy In Cutting Blood Fat Interim ARO-

ARWR had already run hard into the catalyst and remains far above last year’s levels after a 52-week high near $95 in July.

A Lutathera copycat has become the first “radioligand equivalent” cleared by regulators. Elsewhere, Novo dropped the “Nordisk” from its name and a novel RNAi drug showed early promise.

PASADENA, Calif., September 15, 2026--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim topline data from a Phase 1/2a clinical trial of ARO-DIMER-PA, the company’s first investigational RNA interference (RNAi) therapeutic dimer being developed as a potential treatment for atherosclerotic cardiovascular disease (ASCVD) due to mixed hyperlipidemia. ARO-DIMER-PA is designed to silence expression of both proprotein convertase subtilisin kexin 9 (PCSK9) and apolipoprotein C3 (AP

By David Bautz, PhD NASDAQ: ARWR READ THE FULL ARWR RESEARCH REPORT Business Update SHASTA-3 and SHASTA-4 Data Presented at ESC 2026 On August 30, 2026, Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced the presentation of results from the SHASTA-3 and SHASTA-4 trials of plozasiran in patients with severe hypertriglyceridemia (sHTG) at the European Society of Cardiology (ESC) 2026 Meeting.

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) presented detailed results from the randomized, double-blind, placebo-controlled Phase 3 SHASTA-3 and SHASTA-4 studies in 757 adults with severe hypertriglyceridemia. Four quarterly 25-mg doses of plozasiran produced median triglyceride reductions of 79% and 81% at Month 12, compared with approximately 27% for placebo in each study. A prespecified pooled analysis showed […]

Ionis Pharmaceuticals wins regulatory clearance for its quarterly injection, Zanvastro, in Alexander disease. Analysts are focused elsewhere.

PASADENA, Calif., September 03, 2026--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming investor events:

Arrowhead Pharmaceuticals (ARWR) attracted fresh attention after presenting pivotal Phase 3 SHASTA-3 and SHASTA-4 data for plozasiran at the ESC Congress 2026. The company highlighted triglyceride reductions and fewer acute pancreatitis events in severe hypertriglyceridemia. Arrowhead Pharmaceuticals has seen its share price give back some ground in the past week, with the 1-day share price return down 2.97% and the 7-day share price return down 5%. At the same time, the 90-day share price...

PASADENA, Calif., August 30, 2026--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented results from the pivotal Phase 3 SHASTA-3 and SHASTA-4 studies of plozasiran in adults with severe hypertriglyceridemia (sHTG) during a Hot Line Late-Breaking Science session at the European Society of Cardiology (ESC) Congress 2026 in Munich, Germany.